Table 5.

Analyses of EFS From Start of Treatment

VariableMedian EFS5-150 (95% CI)Univariate P Value5-151Multivariate P ValueComment
 
inv16 or t(8; 21) None [65, −]  .003  .029 Unfavorable effect complex −5, −7 increases with time 
Complex −5, −7  10 [8, 15] <.001 <.001  
Other abnormal or IM  24 [17, 32] <.001  .002  
Normal karyotype  46 [30, 76] <.001  —   
PS ≤ 2  31 [27, 37] <.001 <.001 Unfavorable effect PS > 2 levels off by 12 weeks 
PS > 2  4 [2, 10]   —   
LAFR  31 [27, 41] <.001  .003 LAFR favorable only for initial 8 weeks 
No LAFR  17 [11, 24]   —   
IA  52 [37, 81] .003  —  Unfavorable effect F + A disappears by 32 weeks 
IA + G  57 [33, 76] <.001 NS  
F + A  12 [10, 28]  .015  .05  
FLAG  23 [15, 31]  .24 NS  
FLAG + Ida 14.5 [12, 21] <.001 NS  
RAEB  18 [13, 26]  .047 NS  
RAEB-t  30 [21, 46]  .59 NS (.081)  
AML  29 [22, 35]  .48  —   
Age Decreases with increasing age <.001  .001 Unfavorable effect increasing age disappears by 40 wk from start of treatment 
AHD Decreases with length of AHD up to plateau at AHD of 10-20 mo <.001 <.001 
VariableMedian EFS5-150 (95% CI)Univariate P Value5-151Multivariate P ValueComment
 
inv16 or t(8; 21) None [65, −]  .003  .029 Unfavorable effect complex −5, −7 increases with time 
Complex −5, −7  10 [8, 15] <.001 <.001  
Other abnormal or IM  24 [17, 32] <.001  .002  
Normal karyotype  46 [30, 76] <.001  —   
PS ≤ 2  31 [27, 37] <.001 <.001 Unfavorable effect PS > 2 levels off by 12 weeks 
PS > 2  4 [2, 10]   —   
LAFR  31 [27, 41] <.001  .003 LAFR favorable only for initial 8 weeks 
No LAFR  17 [11, 24]   —   
IA  52 [37, 81] .003  —  Unfavorable effect F + A disappears by 32 weeks 
IA + G  57 [33, 76] <.001 NS  
F + A  12 [10, 28]  .015  .05  
FLAG  23 [15, 31]  .24 NS  
FLAG + Ida 14.5 [12, 21] <.001 NS  
RAEB  18 [13, 26]  .047 NS  
RAEB-t  30 [21, 46]  .59 NS (.081)  
AML  29 [22, 35]  .48  —   
Age Decreases with increasing age <.001  .001 Unfavorable effect increasing age disappears by 40 wk from start of treatment 
AHD Decreases with length of AHD up to plateau at AHD of 10-20 mo <.001 <.001 

Abbreviation: NS, not significant.

F5-150

EFS measured in weeks.

F5-151

Log-rank test.

or Create an Account

Close Modal
Close Modal